Aurinia Pharmaceuticals Inc. reported $312M of revenue over the trailing twelve months, +20% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $312M (to Q2 2026). Net income: $314M, trailing twelve months to Q2 2026. Operating margin: 48%, trailing twelve months to Q2 2026. EPS: $2.29, trailing twelve months to Q2 2026.

AUPHAurinia Pharmaceuticals Inc.

Healthcare

$16.65+28% 1Y

$16.65

$11.0552 weeks$18.62

AUPH as reported

Aurinia Pharmaceuticals Inc. reported $312M of revenue over the trailing twelve months, +20% on the year before. 9 reported series are charted on this page, each one as filed.

$312M

Revenue, trailing twelve months · to Q2 2026 · +20% against the twelve months before

Net income: $314M
Net income · +418% year on year · trailing twelve months to Q2 2026
Operating margin: 48%
Operating margin · trailing twelve months to Q2 2026
EPS: $2.29
EPS · +433% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AUPH, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$312M	+20%	Q2 2026
Net income	$314M	+418%	Q2 2026
EPS	$2.29	+433%	Q2 2026
Gross margin	90%	n/a	Q2 2026
Operating margin	48%	n/a	Q2 2026
Net margin	101%	n/a	Q2 2026
ROE	44%	n/a	Q2 2026
ROA	33%	n/a	Q2 2026
P/E	7.27	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.